Document is current
Any future updates will be listed below
-
Authors
Reinhard, Janna
Polke, Markus
Buschulte, Katharina
Eichinger, Monika
Heußel, Claus Peter
Güttlein, Maximilian
Michels-Zetsche, Julia D.
Wielpütz, Mark Oliver
Kahnert, Kathrin
Kontogianni, Konstantina
Klotz, Laura V.
Allgäuer, Michael
Herth, Felix J.
Eberhardt, Ralf
Kreuter, Michael
Trudzinski, Franziska C.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 14 March 2025
First Online: 5 April 2025
Competing interests
: MP received lecture fees from AstraZeneca, Boehringer Ingelheim and Novartis. FCT received payment lectures, or reimbursement of travel expenses from Novartis AG, GlaxoSmithKline, Chiesi, Boehringer Ingelheim GmbH, Grifols and AstraZeneca, CSL Behring and Grifols Deutschland GmbH. MOW reports study grants by Vertex Pharmaceuticals, and advisory board membership at Boehringer Ingelheim and Vertex Pharmaceuticals, KK received lecture fees from AstraZeneca, Boehringer Ingelheim, GSK, Insmed, GlaxoSmithKLine and Chiesi. JDMZ is a board member of the E&H Knorr Stiftung and reports funding by the innovation fund of the G-BA as well as payment or honoraria for lectures from AstraZeneca and reimbursement of travel expenses from CSL Behring. FJH received lecture fees from CSL Behring and Grifols Deutschland GmbH. KKo has received honoraria for lectures from Berlin-Chemie, Astra Zeneca and Boston Scientific, outside the submitted work. MA received lecture fees from Boehringer Ingelheim. KB reports on financial support from the Sarcoidosis Network e.V., consultancy fees from Boehringer-Ingelheim and Astra Zeneca as well as fees for lectures from Boehringer-Ingelheim, Astra Zeneca and Chiesi. CPH has stock ownership in GSK and is a co-inventor of a patent for a method and device for representing the microstructure of the lungs.Dr. Heussel has received consultation and fees from Boehringer Ingelheim, Pfizer, and Exscientia. His research has been funded by Boehringer Ingelheim and Exscientia. He has also received lecture fees from Boehringer Ingelheim and Pfizer. All the remaining authors declare no conflict of interest.
: The study was approved by the Institutional Review Board Ethics Committee of the Medical Faculty of Heidelberg University (S-382/2023). Informed consent was waived by the Ethics Committee due to the retrospective nature of the study. The study was conducted in accordance with the principles of the Declaration of Helsinki.
